May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS
The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing forms of MS (see “FDA Approves Ozanimod for MS”).

Expanded label for Dupixent
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Dupixent dupilumab in children aged 6 to 11 with moderate-to-severe atopic dermatitis. The mAb against IL-4 and IL-13 is the only biologic approved for this population, according to the companies. ...